Edition:
United Kingdom

Imv Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

7.13CAD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$7.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
35,303
52-wk High
$9.49
52-wk Low
$5.18

Summary

Name Age Since Current Position

Andy Sheldon

2016 Chairman of the Board

Frederic Ors

42 2016 Chief Executive Officer, Director

Pierre Labbe

52 2017 Chief Financial Officer

Joseph Sullivan

2018 Senior Vice President - Business Development

Marc Jasmin

2018 Senior Director, Director of Investor Relations

Gabriela Rosu

2016 Chief Medical Officer

Marc Mansour

40 2016 Director

Julia Gregory

65 2018 Director

Albert Scardino

66 2016 Director

Shermaine Tilley

Director

Markus Warmuth

2018 Director

James Hall

68 2010 Independent Director

Wayne Pisano

63 2011 Independent Director

Biographies

Name Description

Andy Sheldon

Mr. Andy Sheldon is Chairman of the Board of the company. He has been President and Chief Executive Officer of Medicago since August 2003. He has thirty years of experience in the pharmaceutical industry, and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012. Before joining Medicago, Mr. Sheldon served as Vice President, Sales and Marketing, of Shire Biologics. He was responsible for international expansion with European, American and Asian private partnership agreements. During his tenure at Shire, his notable accomplishments included negotiating the annual and pandemic influenza vaccine contract with the federal and provincial governments, and managing the approval of a bladder cancer therapeutic vaccine by the U.S. Food and Drug Administration (FDA). Mr. Sheldon has a bachelor's degree in agricultural sciences from Universite Laval, Quebec City, and a bachelor's of science degree with honors in biological sciences from the University of East Anglia, in Norwich, England.

Frederic Ors

Mr. Frederic Ors is Chief Executive Officer, Director of ImmunoVaccine Inc., He spent 13 years at Medicago Inc. in Quebec, most recently as vice-president of business development and strategic planning. He has been an integral part of Medicago's success in securing multiple non-dilutive financing opportunities, leading to an acquisition by Mitsubishi Pharma in 2013 for $357-million. Before joining Medicago, he was manager of intellectual property and licensing for Paris Diderot University, a complex of 150 labs, two hospitals and 2,300 scientists in Paris. He earned his bachelor's degree in biology and his master's degree in management of innovation projects in biotechnology at the University of Angers.

Pierre Labbe

Mr. Pierre Labbe is Chief Financial Officer of the Company. Mr. Labbé brings to Immunovaccine more than 15 years of experience in the role of chief financial officer, having served in that capacity with, among others, Medicago Inc. and Leddartech Inc. He was an integral part of the team that negotiated the acquisition of Medicago by Mitsubishi Tanabe Pharma in 2013 for an enterprise value of $357 million Canadian dollars. He has also been responsible for numerous rounds of private and public financing, initial public offerings preparation and execution, and establishment of key strategic alliances. Mr. Labbé currently serves on the Boards of Directors of several publicly traded, Canadian-based companies. He earned his Bachelor’s degree from Université Laval, and holds CA and ICD designations.

Joseph Sullivan

Mr. Joseph Sullivan has been appointed Senior Vice President - Business Development of the Company effective Jan. 22, 2018. Mr. Sullivan's pharmaceutical career has focused on leading product teams and external collaborations, identifying novel vaccine targets and technologies for development, and operationalizing global launch and commercialization plans. Most recently, he served as the Executive Director, Partner Strategy and Implementation Lead, at Merck & Co Inc. Prior to holding that position, he led the New Vaccines Product Group responsible for commercial direction of new vaccine development. His breadth of commercial experience includes leading the introduction of Gardasiltrademark in the US, which achieved over $1 billion of revenue in the first year, and the expansion of Singulairtrademark into the respiratory markets.i.

Marc Jasmin

Mr. Marc Jasmin is Senior Director, Director of Investor Relations of the company. For the last 15 years, Mr. Jasmin has served in a broad range of investor and communications-focused positions. His experience includes overseeing the investor relations department of Cascades (CAS/TSX) and serving as Director, Investor Relations, of Boralex (BLX/TSX), the latter of which has a market cap over $1.5B CAD and is ` in Canada and France in the renewable energy space. Under his leadership, both Cascades and Boralex were nominated as best overall investor relations, or investor relations officer, in applicable categories. Prior to these positions, Mr. Jasmin spent seven years in various financial and investor-focused roles, ranging from financial advisor for a large Canadian brokerage firm to an institutional salesperson. Mr. Jasmin earned his BAA and Certificate of Accounting from the University of Montreal. He is a member of the Quebec Order of Chartered Professional Accountants (CPA, CMA).

Gabriela Rosu

Dr. Gabriela Rosu is Chief Medical Officer of the Company. She brings to Immunovaccine more than 15 years of broad clinical and pharmaceutical industry experience that spans the entire value chain of pharmaceutical development, from early-phase discovery to post-marketing commercialization. Most recently, Dr. Rosu was appointed the Medical Science Liaison, Haematology Oncology, at Janssen Inc., where she was responsible for the regional medical strategy implementation for targeted and immuno-modulating therapy in chronic lymphocytic leukemia (CLL) and multiple myeloma. Prior to this position, she served as the Global Medical Advisor in Haematology at Novo Nordisk, where she actively participated in developing the global medical strategy and clinical development plans for multiple compounds. Her duties included overseeing clinical trial planning, activities and publications for early development-phase compounds, as well as regulatory filing support and post-approval commitments for late-stage candidates and marketed products. Her experience in these positions included developing and implementing medical programs and participating in the development and review of medical and marketing materials. She played instrumental roles in international advisory boards, organized collaborations with research partners, and networked with key opinion leaders in support of her programs.

Marc Mansour

Dr. Marc Mansour Ph.D., is Director of the Company. Dr. Mansour is an expert in vaccinology and cancer immunotherapy. Since he joined Immunovaccine, Dr. Mansour has led the clinical development of the DepoVax™ platform and the Corporations’ lead therapeutic cancer vaccine DPX-Survivac. He represents the Corporation to the investor and scientific communities. He continues to lead the internal development of vaccines based on the DepoVax™ platform, and externally with collaborators and commercial partners. Dr. Mansour holds a Ph.D. in biology and an MBA.

Julia Gregory

Ms. Julia P. Gregory is Director of the Company. Ms. Gregory is a seasoned biotechnology executive with chief executive officer, chief financial officer, board and investment banking experience. She recently served as chief executive officer and board member of ContraFect Corp., a public biotechnology company developing innovative anti-infectives. Prior to this engagement, she served as the chief executive officer of the immuno-oncology company Five Prime. Ms. Gregory has a proven record of successfully growing, capitalizing, and positioning private and public biotechnology companies. As a biotechnology executive, she has raised more than $1.5-billion across all types of business cycles and structured creative strategic alliances and transactions with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Genentech Inc. (now Roche) and Human Genome Sciences (now GSK). She is currently on the board of directors of Iconic Therapeutics, the Sosei Group and Biohaven Therapeutics.

Albert Scardino

Mr. Albert James Scardino is Director of ImmunoVaccine Inc. Mr. Scardino is a journalist, media investor and communications strategist. He has extensive experience as a director of both for-profit and not-for-profit organizations, public and private, in the US and the UK. He has written and served as an editor for his own newspaper, The Georgia Gazette (where he won a Pulitzer Prize), as well as for The New York Times and The Guardian. He has served as a communications director in political campaigns and government and as a commentator and media critic for national and international news organisations. He earned his bachelor’s degree at Columbia University and his master’s at the University of California, Berkeley. He has been an investor in Immunovaccine since 2005, a director since 2010 and chairman since 2011.

Shermaine Tilley

Ms. Shermaine Tilley, Ph.D. is the Director of the Company. Prior to joining CTI LSF, Dr. Tilley was a Senior Vice President at Drug Royalty Corporation (DRC), where she led operations overseeing the royalty transactions in the biotech/pharma space. At DRC (now DRI), Dr. Tilley played a leading role in closing 12 transactions totaling over $200 million in investments. Dr. Tilley has also held positions managing a research laboratory and serving as a faculty member at the NYU School of Medicine and Public Health Research Institute (PHRI), and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program in immunology and infectious disease for 10 years. She holds a PhD in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto, and is a member of the CFA Society of Toronto. She currently sits on the boards of Phemi, Xagenic, Zymeworks and BIOTECanada.

Markus Warmuth

Dr. Markus Warmuth is Director of the Company. Prior to his role at Third Rock, Dr. Warmuth spent seven years as the Chief Executive Officer of H3 Biomedicine, a biopharmaceutical company that specializes in the discovery and development of precision oncology treatments. While at H3, he was instrumental in the company's successful progress from a drug discovery engine to a clinical stage organization with a specialized focus on genomics-based oncology drug candidates and novel immune-oncology approaches. Previous to his role at H3, he served in various positions of increasing responsibility at the Novartis Institute for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology and Head of Oncology Pharmacology. In these roles, he focused on developing data-driven, science-based drug discovery programs, with a specialization in novel anti-cancer therapies. Dr. Warmuth earned his MD from Ludwig Maximilian University, in Munich, Germany. He joins the Board of Directors at IMV as current board member Alfred Smithers, President and Chief Executive Officer of Iona Resources Holdings Limited, departs.

James Hall

Mr. James W. Hall, C.A., is an Independent Director of Immunovaccine Inc., since February 22, 2010. Mr. Hall is Vice President of Callidus Capital Corporation – a specialized asset-based lender to companies in Canada and the United States. He is also President of James Hall Advisors Inc., a financial and management advisory firm. Prior to James Hall Advisors Inc., Mr. Hall was Chairman and Chief Executive Officer of Philadelphia-based pure-play newspaper company Journal Register Company, and served as Senior Vice President & Chief Investment Officer of private equity investment fund Working Ventures Canadian Fund Inc. from 1990 to 2002. Mr. Hall is a director of Indigo Books & Music Inc., Atomic Energy of Canada Limited, Adventus Intellectual Property Inc., and Trustee of an OMERS Trust. A Chartered Accountant (CPA, CA), Mr. Hall is a graduate of the Richard Ivey School of Business at Western University in London, Ontario.

Wayne Pisano

Mr. Wayne Pisano serves as an Independent Director of Immunovaccine Inc., since October 17, 2011. Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He is currently the President and CEO of VaxInnate a privately held biotech company. He joined Immunovaccine’s board in October 2011 with a depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development. Mr. Pisano is the former President and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997 and was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. During his tenure as CEO, Mr. Pisano bolstered the Sanofi Pasteur pipeline with the acquisitions of Acambis PLC, a bio-tech based in Boston in 2008 and Shantha Biotechnics, a highly regarded Indian vaccine company in 2010. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor’s degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.